Literature DB >> 12810674

Ovarian carcinoma develops through multiple modes of chromosomal evolution.

Mattias Höglund1, David Gisselsson, Gunnar B Hansen, Torbjörn Säll, Felix Mitelman.   

Abstract

Ovarian carcinoma has the highest mortality of all of the gynecologic cancers. The chromosomal changes in this tumor type are highly complex, and the karyotypes typically show severe aneuploidy. Despite the abundance of cytogenetic information, with approximately 400 published karyotypes, very little is known about the mode of karyotypic evolution and the possible presence of cytogenetic pathways related to tumor development. In the present investigation we used 387 ovarian carcinoma karyotypes to identify the most frequent genomic imbalances. Tumor cases were then classified with respect to the presence or absence of these imbalances and statistically analyzed to assess the order of appearance of chromosomal imbalances, as well as possible karyotypic pathways and cytogenetic subtypes. We establish the temporal order by which the different imbalances occur and show that at least two cytogenetic pathways exist, one characterized by +7, +8q, and +12, and one by 6q- and 1q-. We show that ovarian carcinomas develop through at least three phases of karyotypic evolution. At the early stages, Phase I, the karyotypic evolution seems to proceed though step-wise acquisition of changes. The transition to Phase II showed signs of an increased chromosomal instability, most probably caused by extensive telomere crisis and the onset of breakage-fusion-bridge cycles. This process was linked to the presence of imbalances characteristic for the 6q-/1q- pathway. The transition to Phase III involved triploidization and was also linked to the presence of the 6q-/1q- pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810674

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Julieta Panero; Jorge Arbelbide; Dorotea Beatriz Fantl; Hernán García Rivello; Dana Kohan; Irma Slavutsky
Journal:  Mol Med       Date:  2010-07-14       Impact factor: 6.354

Review 2.  Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

Authors:  Analisa DiFeo; Goutham Narla; John A Martignetti
Journal:  Mt Sinai J Med       Date:  2009-12

3.  FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer.

Authors:  Elsa De La Chesnaye; Juan Pablo Méndez; Ricardo López-Romero; María De Los Angeles Romero-Tlalolini; María Dolores Vergara; Mauricio Salcedo; Sergio R Ojeda
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.

Authors:  Kylie L Gorringe; Joshy George; Michael S Anglesio; Manasa Ramakrishna; Dariush Etemadmoghadam; Prue Cowin; Anita Sridhar; Louise H Williams; Samantha E Boyle; Nozomu Yanaihara; Aikou Okamoto; Mitsuyoshi Urashima; Gordon K Smyth; Ian G Campbell; David D L Bowtell
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

5.  Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas.

Authors:  Christine S Walsh; Seishi Ogawa; Daniel R Scoles; Carl W Miller; Norihiko Kawamata; Steven A Narod; H Phillip Koeffler; Beth Y Karlan
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

6.  Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression.

Authors:  Julia K Soo; Alastair D Mackenzie Ross; David M Kallenberg; Carla Milagre; W Heung Chong; Jade Chow; Lucy Hill; Stacey Hoare; Rebecca S Collinson; Mehnaz Hossain; W Nicol Keith; Richard Marais; Dorothy C Bennett
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-20       Impact factor: 4.693

7.  Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.

Authors:  Paule Héléna Yoffou; Lydia Edjekouane; Liliane Meunier; André Tremblay; Diane Michèle Provencher; Anne-Marie Mes-Masson; Euridice Carmona
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

8.  Proximal and distal regulation of the HYAL1 gene cluster by the estrogen receptor α in breast cancer cells.

Authors:  Lydia Edjekouane; Samira Benhadjeba; Maïka Jangal; Hubert Fleury; Nicolas Gévry; Euridice Carmona; André Tremblay
Journal:  Oncotarget       Date:  2016-11-22

9.  NuMA overexpression in epithelial ovarian cancer.

Authors:  Anke Brüning-Richardson; Jaqueline Bond; Rawiah Alsiary; Julie Richardson; David A Cairns; Luci McCormac; Richard Hutson; Philip A Burns; Nafisa Wilkinson; Geoff D Hall; Ewan E Morrison; Sandra M Bell
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

10.  Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas.

Authors:  David Gisselsson; Gisela Lundberg; Ingrid Ora; Mattias Höglund
Journal:  J Carcinog       Date:  2007-09-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.